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Abstract
Purpose: MAPK and PI3K/AKT/mTOR pathways play impor-
tant roles inmany tumors. In this study, safety, antitumor activity,
and pharmacokinetics of buparlisib (pan class PI3K inhibitor)
and trametinib (MEK inhibitor) were evaluated.
Experimental Design: This open-label, dose-ﬁnding, phase Ib
study comprised dose escalation, followed by expansion part in
patients with RAS- or BRAF-mutant non–small cell lung, ovarian,
or pancreatic cancer.
Results:Ofnote, 113 patientswere enrolled, 66 and 47 in dose-
escalation and -expansion parts, respectively. MTD was estab-
lished as buparlisib 70 mgþ trametinib 1.5 mg daily [5/15, 33%
patients with dose-limiting toxicities (DLT)] and recommended
phase II dose (RP2D) buparlisib 60mgþ trametinib 1.5mg daily
(1/10, 10%patientswithDLTs).DLTs included stomatitis (8/103,
8%), diarrhea, dysphagia, and creatine kinase (CK) increase
(2/103, 2% each). Treatment-related grade 3/4 adverse events
(AEs) occurred in 73 patients (65%); mainly CK increase, stoma-
titis, AST/ALT (aspartate aminotransferase/alanine aminotrans-
ferase) increase, and rash. For all (21) patients with ovarian
cancer, overall response rate was 29% [1 complete response, 5
partial responses (PR)], disease control rate 76%, and median
progression-free survival was 7 months. Minimal activity was
observed in patients with non–small cell lung cancer (1/17 PR)
and pancreatic cancer (best overall response was SD). Relative to
historical data, buparlisib exposure increased and trametinib
exposure slightly increased with the combination.
Conclusions: At RP2D, buparlisib 60 mg þ trametinib 1.5
mg daily shows promising antitumor activity for patients with
KRAS-mutant ovarian cancer. Long-term tolerability of the
combination at RP2D is challenging, due to frequent dose
interruptions and reductions for toxicity. Clin Cancer Res; 21(4);
730–8. 2014 AACR.
Introduction
The MAPK and the PI3K/AKT/mTOR (PI3K) pathways are
frequently dysregulated in cancer. Molecular alterations in these
pathways are implicated in tumorigenesis and resistance to anti-
cancer therapies (1). KRAS mutations are found most frequently
in pancreatic cancer (70%–90%; ref. 2), non–small cell lung
cancer (NSCLC; 20%–30%; ref. 3), and colorectal cancer
(30%–40%; ref. 4), whereas BRAF mutations occur in approxi-
mately 8% of human tumors, most frequently in melanoma
(40%–60%; ref. 5), thyroid (39%), colorectal cancer (12%), and
ovarian cancers (12%; ref. 6).
MAPK and PI3K pathways converge at multiple points, and
preclinical data suggest that dual blockade may be synergistic
(1, 7, 8), thus providing a rationale for evaluating safety, toler-
ability, and efﬁcacy of PI3K and MEK inhibitor combinations in
patients with tumors bearing genetic aberrations of these
pathways.
Buparlisib (BKM120) is a potent and highly speciﬁc oral pan-
class I PI3K inhibitor that does not inhibit mTOR and Vps34
kinases (9). MTD and recommended phase II dose (RP2D) of
single-agent oral buparlisib are 100 mg/d (10). Key toxicities
include hyperglycemia, neuropsychiatric disorders, liver toxicity,
skin rash and hypersensitivity, and gastrointestinal toxicity. Tra-
metinib (GSK1120212; Mekinist) is a reversible, highly selective
allosteric inhibitor of MEK1/MEK2 activation and kinase activity
(11, 12). MTD and RP2D of trametinib are 3 and 2 mg/d,
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respectively (13, 14). Key toxicities include rash, gastrointestinal
effects, cardiac and vascular disorders, ocular toxicities, and inter-
stitial lung disease. Trametinib has been approved as monother-
apy for unresectable or metastatic BRAF V600E/K mutation-pos-
itive melanoma in the United States and Canada.
The aim of this phase Ib study was to determine MTD and/or
RP2D for buparlisib combined with trametinib when adminis-
tered orally to adult patients with selected advanced solid tumors,
and then to evaluate safety and preliminary antitumor activity of
MTD and/or RP2D in patients with advanced NSCLC, ovarian
cancer, or pancreatic cancer with RAS or BRAF mutations in the
expansion part of the study (clinicaltrials.gov registry identiﬁer
NCT01155453).
Materials and Methods
Study design and patient population
This phase Ib study was conducted at 7 hospitals across 5
countries in the United States, Canada, and Europe. Accrual
period was May 2010 to January 2013. Dose-escalation part
enrolled adult patients with advanced solid tumors harboring
RAS or BRAF mutations such as colorectal cancer, melanoma,
NSCLC, triple-negative breast cancer (TNBC), or pancreatic can-
cer. When MTD was deﬁned, dose-expansion part was conducted
in adult patients with measurable and evaluable (by RECIST
version 1.0) advanced NSCLC, ovarian, or pancreatic cancer with
RAS or BRAF mutations. Patients had baseline World Health
Organization (WHO) performance status (PS) 0 to 2, and ade-
quate organ function. Patients with anxiety assessed as grade 3
[National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE), version 4] or ocular/retinal comorbid-
ities associatedwith increased risk of central serous retinopathy or
retinal vein occlusion were excluded. Prior treatment, including
PI3K or MEK inhibitor therapy, was permitted if it had ended at
least 4 weeks (or >1 cycle) before initiating study medication.
Treatment was discontinued in cases of unacceptable toxicity,
disease progression, at discretion of the investigator or by patient
withdrawal.
This studywas performed in accordancewith theDeclaration of
Helsinki and the principles of Good Clinical Practice. The pro-
tocol was approved by an Institutional Review Board at each
hospital, and all patients provided written informed consent
before any study procedures.
Procedures
Buparlisib capsules and trametinib tabletswere coadministered
orally once daily in a 28-day cycle. First cohort received 30mg/dof
buparlisibþ 0.5mg/d trametinib. Doses were escalated according
to an adaptive Bayesian logistic regression model (BLRM) with
overdose control principle until MTD and/or RP2D was reached
(Fig. 1A and B; refs. 15, 16). Dose escalation could not exceed
MTD of either agent as monotherapy, and only one drug was
escalated at a time. Cohorts of 3 to 6 evaluable patients were
enrolled per dose combination. Multiple dose combinations
couldbe studied simultaneously. Primary endpointwas incidence
rate of dose-limiting toxicities (DLT) in cycle 1.DLTwasdeﬁned as
an adverse event (AE) or abnormal laboratory value assessed as at
least possibly related to study medication, which also met the
prespeciﬁed DLT criteria. AEs were classiﬁed according to NCI
CTCAE version 4. Dose modiﬁcations were permitted for treat-
ment-related toxicity. All patients underwent ophthalmologic
examinations at baseline, each cycle completion, end of study,
and as clinically warranted. Secondary objectives were safety,
pharmacokinetics (PK), efﬁcacy, and predictive/pharmacody-
namic (PD) biomarkers. Tumor response was classiﬁed according
to RECIST version 1.0.
Blood samples for serial PK evaluation for both buparlisib and
trametinib were collected on days 1, 15, and 28 of cycle 1 in dose-
escalation part; and on day 28 of cycle 1 in expansion part.
Archival and fresh tumor tissue samples, whenever feasible,
were collected at baseline and at cycle 1 day 28 (dose-escalation
part) or at baseline and day 15 (dose-expansion part) to inves-
tigate PD effects on molecular signaling, a secondary objective,
and to evaluate potential biomarkers predictive of efﬁcacy, an
exploratory objective. Assessments included biomarker status/
levels pre- versus posttreatment for PD and antitumor effect, S6
(p-S6) and ERK (p-ERK) phosphorylation, measured by immu-
nohistochemistry (IHC). In addition, exploratorymolecular alter-
ation analysis on markers relevant to PI3K and MAPK pathways,
such as PTEN protein expression and PIK3CA alteration, was
completed on tumor tissue via IHC and next-generation sequenc-
ing, respectively.
Statistical analysis
The BLRM was ﬁtted on the cycle 1 DLT data accumulated
throughout the dose escalation to model the dose-toxicity rela-
tionship of buparlisib and trametinib when given in combina-
tion. At each decision time point, the adaptive BLRM identiﬁed
combinations that meet the Escalation with Overdose Control
criteria so that only combinations associated with a risk of
excessive toxicity less than 25% could be considered for the next
dose cohort. Dose recommendations were based on posterior
summaries for each dose combination, including the mean,
median, SD, 95% credibility interval, and the interval probabil-
ities for under dosing (DLT rate >0.16), targeted (DLT rate
between 0.16 and 0.35), and excessive toxicity (DLT rate
> 0.33). A clinical synthesis of available toxicity information
(including AEs that were not DLTs and laboratory tests), PK, PD,
and efﬁcacy information, as well as recommendations from the
Translational Relevance
The MAPK and PI3K/AKT/mTOR (PI3K) pathways are fre-
quently dysregulated inmany cancers.Molecular alterations in
these pathways, including KRAS mutations, are implicated in
tumorigenesis and resistance to anticancer therapies. These
pathways converge at multiple points, and preclinical data
suggest that dual blockade may be advantageous, providing a
rationale for evaluating safety, tolerability, and efﬁcacy of PI3K
and MEK inhibitor combinations in patients with tumors
bearing genetic aberrations of these pathways. This article
demonstrates clinical activity in patients with ovarian cancer
who are treated with a combination of buparlisib (PI3K
inhibitor) and trametinib (MEK inhibitor). Furthermore, it
appears that subtypes of ovarian cancer may be disposed to
react differently, with KRAS G12V-mutated versions seeming
to beneﬁt more from combination treatment. As ovarian
cancer is still a disease for which there is large unmet medical
need, further studies to investigate these ﬁndings are recom-
mended, including extensive biomarker analysis.
PI3K Inhibitor Buparlisib with MEK Inhibitor Trametinib
www.aacrjournals.org Clin Cancer Res; 21(4) February 15, 2015 731
on February 17, 2016. © 2015 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst December 10, 2014; DOI: 10.1158/1078-0432.CCR-14-1814 
BLRM, were used to determine dose combination for the next
cohort. Investigators, Novartis and GSK trial personnel partici-
pated in decision making. Selected doses could not violate over-
dose criteria. AEs, overall response rates (ORR), disease control
rate (DCR), progression-free survival (PFS), duration of stable
disease (SD), and overall survival (OS) were summarized.
Results
As of July 18, 2013, 113 patients were enrolled and treated with
buparlisib and trametinib; all included in safety and efﬁcacy
analyses. Baseline characteristics are summarized in Table 1. Nine
combination dose levels were explored during dose escalation,
varying from 30 to 90 mg for buparlisib and 0.5 to 2.0 mg for
trametinib in a total of 66 patients (Fig. 1A and B). MTD was
deﬁned as 70 mg buparlisib and 1.5 mg trametinib. The BLRM
indicated that estimated DLT rate at MTD and RP2D were 23%
and 18%, respectively, and the posterior risk of DLT rate being in
the excessive toxicity category was less than 0.1% for both MTD
and RP2D, and thus met the EWOC criteria. Twelve (19%) of 62
evaluable patients during dose escalation experiencedDLTs, all of
which were reversible (Fig. 1B).
There were 5 of 15 (33%) evaluable patients with DLTs in the
MTD cohort and 1 of 10 (10%) in the RP2D cohort.Most frequent
DLTs among all evaluable patients were stomatitis (8/103, 8%),
diarrhea, dysphagia, and creatine kinase (CK) increase (2/103, 2%
each).
A: Dose-escalation schedule
30 mg + 0.5 mg +Buparlisibdose
Trametinib
dose
60 mg + 0.5 mg
60 mg + 1.0 mg
60 mg + 1.5 mg 80 mg + 1.0 mg
60 mg + 2.0 mg 80 mg + 1.5 mg
60 mg + 1.5 mg
60 mg + 2.0 mg
90 mg + 1.0 mg
70 mg + 1.5 mg
70 mg + 1.5 mg
Expansion phase
MTD: 70 mg + 1.5 mg RP2D: 60 mg + 1.5 mg
B: DLTs during dose-escalation part
Cohort
1 30 mg 0.5 mg 4 4 0
2 60 mg 0.5 mg 5 5 0
3 60 mg 1.0 mg 6
6
6
5 3
6
6 6
5 0
5
5 5 1
4 0
4 4
4
1
1 G3 stomatitis
G3 stomatitis, G3 dysphagia
dysphagia, G2 diarrhea)
Skipped/delayed dose (G2 stomatitis)
G3 stomatitis
4.1
4.2
5.1
5.2
6
7.1
7.2
8.1
8.2
9
All
As of July 18, 2013.
1 - Number of patients treated:
2 - Number of evaluable patents.
3 - Patients may have more than one DLT.
G - grade; CK - creatine kinase; LVEF - left ventricular ejection fraction.
66 62 12
60 mg
80 mg
80 mg
60 mg
60 mg 2.0 mg 4 4 1
1.0 mg 4 4 0
1.5 mg
1.5 mg
1.5 mg
60 mg 2.0 mg
60 mg
70 mg
90 mg
70 mg
1.5 mg
1.5 mg
1.0 mg
1.5 mg 6 5 0
5 5 1 G3 type II diabetes, G3 hyperlipasemia
G3 CK elevation, 20% LVEF decrease, G3
G3 CK elevation, skipped/delayed dose (G2
nausea, G3 decreased appetite,
G3 decreased oral intake
#
Buparlisib Trametinib N1 N2 DLT Nature of DLT3
Figure 1.
Dose-escalation schedule and DLTs
during dose-escalation part.
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MTD was initially used during expansion part; however, after
review of tolerability of ﬁrst 10 patients enrolled, this dose was
revised because of high incidence of AEs (mainly stomatitis and
rash). On the basis of the Bayesian inference of the dose–DLT
relationship using DLT information from patients enrolled in the
dose-escalation part, aswell as patients enrolled at theMTD level in
dose-expansionpart, theBLRMestimated that combinationdoseof
60 mg buparlisib with 1.5 mg trametinib satisﬁes the EWOC
criteria, and this dosewas established following review of available
data as RP2D. All new patients were subsequently enrolled to the
starting dose of RP2D of 60 mg buparlisib and 1.5 mg trametinib.
In total, 47 patients were treated during dose expansion.
Table 1. Baseline characteristics of patients enrolled
Dose escalation Dose expansion All patients
Demographics N ¼ 66 N ¼ 47 N ¼ 113
A. All patients
Age at baseline, y, Median (range) 57.0 (29.0–84.0) 56.0 (25.0–72.0) 56.0 (25.0–84.0)
Sex, n (%)
Male 30 (45.5) 19 (40.4) 49 (43.4)
Female 36 (54.5) 28 (59.6) 64 (56.6)
WHO performance status, n (%)
0 29 (43.9) 16 (34.0) 45 (39.8)
1 37 (56.1) 30 (63.8) 67 (59.3)
2 0 1 (2.1) 1 (0.9)
Primary tumor type, n (%)
CRC 33 (50.0) 0 33 (29.2)
Pancreatic 9 (13.6) 15 (31.9) 24 (21.2)
Cutaneous melanoma 9 (13.6) 0 9 (8.0)
Ovarian 4 (6.1) 17 (36.2) 21 (18.6)
TNBC 4 (6.1) 0 4 (3.5)
NSCLC 2 (3.0) 15 (31.9) 17 (15.0)
Othera 4 (6.1) 0 4 (3.5)
Missing 1 (1.5) 0 1 (0.9)
Local molecular statusb
KRAS mutation 41 (62.1) 43 (91.5) 84 (74.3)
NRAS mutation 6 (9.1) 0 6 (5.3)
BRAF mutation 9 (13.6) 3 (6.4) 12 (10.6)
Number of prior antineoplastic regimens, n (%), Median (range) 3 (1–8) 3 (1–14) 3 (1–14)
Demographics Ovarian cancer
patients (N ¼ 21)
B. Ovarian cancer patients
Age at baseline, y, median (range) 49.0 (25.0–68.0)
WHO performance status, n (%)
0 11 (52.4)
1 10 (47.6)
2 0
Histologic grade, n (%)
Well differentiated 15 (71.4)
Moderately differentiated 3 (14.3)
Poorly differentiated 2 (9.5)
Undifferentiated —
Unknown 1 (4.8)
Details of tumor histology/cytology, n (%)
Adenocarcinoma 3 (14.3)
Papillary serous/serous adenocarcinoma 13 (61.9)
Mucinous adenocarcinoma 1 (4.8)
Clear cell adenocarcinoma 1 (4.8)
Other 3 (14.3)
Stage at initial diagnosis, n (%)
Stage I (a–c) 6 (28.6)
Stage II (a–c) 3 (14.3)
Stage III 5 (23.8)
Stage III (a–c) 7 (33.3)
Stage IV —
Local molecular statusb
KRAS mutation 19 (90.5)
BRAF mutation 1 (4.8)
Number of prior antineoplastic regimens, n (%), median (range) 3 (1–14)
Abbreviation: CRC, colorectal cancer.
aIncludes 1 patient with thyroid cancer, 1 patient with ampullary cancer, 1 patient with choroid melanoma of the eye, and 1 patient with endocervical cancer.
bDuring dose-escalation part, patients with pancreatic cancer or TNBC irrespective of mutation status were enrolled. One patient with granulosa cell tumor of the
ovary with a RASA1 mutation was enrolled during the dose-expansion phase.
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A total of 110 (97%) patients experienced AEs considered by
investigators to be treatment related. Overall, 73 (65%) of 113
patients experienced treatment-related grade 3/4 AEs; most fre-
quent (>5%) were CK increase (16/113, 14%), ALT (alanine
aminotransferase) increase, and stomatitis (10/113, 9% each),
maculo-papular rash and macular rash (9/113, 8% each), AST
(aspartate aminotransferase) increase (7/113, 6%), thrombocy-
topenia, and dermatitis acneiform (6/113, 5% each; Table 2).
Incidence of treatment-related grade 3/4 AEs at MTD and RP2D
were 82% (28 AEs) and 58% (23 AEs), respectively.
Serious AEs (SAE) related to treatment were experienced by 21
of 113 (19%)patients;most frequentwere stomatitis (5/113, 4%)
and diarrhea (4/113, 4%). At MTD and RP2D, 9 (27%) and 5
(13%) of 40 patients, respectively, experienced treatment-related
SAEs. No treatment-related deaths were observed.
Thirty-ﬁve (31%) of 113 patients permanently discontinued
study drugs due to AEs,most commonofwhichwere ALT increase
and rashmacular (4/113, 4% each). AtMTD and RP2D, 15 (44%)
and 8 (20%) patients, respectively, discontinued study treatment
due to AEs. AEs requiring dose interruption and/or dose reduc-
tions were experienced by 79 patients (70%) overall, of which
most frequently reported (10%)were stomatitis (18/113, 16%),
CK increase (15/113, 13%), and ALT increase (14/113, 12%). At
MTD and RP2D, 29 (85% and 73%, respectively) patients,
reported AEs requiring dose interruption and/or dose reductions.
At theMTD, 20patients (58.8%) treatedwith buparlisib and 22
patients (64.7%) treated with trametinib had a relative dose
intensity 75%. At the RP2D, 39 patients (97.5%) treated with
buparlisib and 26 patients (65%) treated with trametinib had a
relative dose intensity 75%.
Pharmacokinetics
Buparlisib was absorbed rapidly following oral administration
(median Tmax was 2.17 (1.0–12.3) hours at RP2D on cycle 1 day
15. After reaching peak plasma drug concentration (Cmax), bupar-
lisib concentrations decreased in a biexponential manner. At
RP2D, geometric mean values of Cmax and AUC0-24 on cycle 1
day 1 and cycle 1 day 15 were 340.87 ng/mL [coefﬁcient of
variation (CV)% 50.80] and 3,106.81 ngh/mL (CV% 32.29) and
522 ng/mL (CV% 50.1), and 6,607 ngh/mL (CV% 32.3), respec-
tively. Geometric mean values of the accumulation ratio on cycle
1 day 15 and day 28 at RP2D dose level were found to be 2.12
(CV% 47.04) and 2.05 (CV% 48.88), respectively (Fig. 2).
The plasma concentration–time proﬁle of trametinib also
showed rapid absorption with a median Tmax of 2.95 (1.5–
12.3) hours at RP2D on cycle 1 day 15 (Fig. 2). Geometric
means of Cmax and AUC0-24 after a single dose at RP2D were
3.36 ng/mL (CV% 69.10) and 29.60 ngh/mL (CV% 33.56).
Geometric mean values of Cmax and AUC0-24 on cycle 1 day 15
at RP2D and at MTD for Cmax were 19 ng/mL (CV% 33.3), and
16 ng/mL (CV% 159.5), and for AUC0-24 were 325 ngh/mL
(CV% 32.2), and 391 ngh/mL (CV% 50.1), respectively. Geo-
metric mean values of the accumulation ratio on cycle 1 day 15
and day 28 at RP2D dose level were found to be 9.95 (CV%
28.55) and 10.37 (CV% 23.99), respectively. Steady state was
achieved within 15 days for both drugs.
Table 2. Treatment-related AEs occurring in 5% of patients overall (all grades and grades 3–4; at RP2D, MTD, and overall)
Buparlisib 60 mg þ trametinib
1.5 mg (N ¼ 40)
Buparlisib 70 mg þ trametinib
1.5 mg (N ¼ 34) All patients (N ¼ 113)
n (%) n (%) n (%)
Grades Grades Grades
Preferred term All 3–4 All 3–4 All 3–4
Total 39 (97.5) 23 (57.5) 33 (97.1) 28 (82.4) 110 (97.3) 73 (64.6)
Dermatitis acneiform 16 (40.0) 1 (2.5) 22 (64.7) 4 (11.8) 58 (51.3) 6 (5.3)
Diarrhea 18 (45.0) 0 23 (67.6) 4 (11.8) 55 (48.7) 5 (4.4)
Blood CK increased 20 (50.0) 6 (15.0) 17 (50.0) 6 (17.6) 51 (45.1) 16 (14.2)
Stomatitis 17 (42.5) 2 (5.0) 17 (50.0) 5 (14.7) 46 (40.7) 10 (8.8)
Nausea 13 (32.5) 0 9 (26.5) 0 35 (31.0) 2 (1.8)
Rash macular 9 (22.5) 1 (2.5) 11 (32.4) 7 (20.6) 29 (25.7) 9 (8.0)
Rash maculo-papular 11 (27.5) 2 (5.0) 10 (29.4) 2 (5.9) 29 (25.7) 9 (8.0)
Vomiting 11 (27.5) 0 9 (26.5) 0 28 (24.8) 0
AST increased 8 (20.0) 3 (7.5) 6 (17.6) 1 (2.9) 22 (19.5) 7 (6.2)
Fatigue 11 (27.5) 2 (5.0) 5 (14.7) 0 22 (19.5) 2 (1.8)
ALT increased 6 (15.0) 2 (5.0) 7 (20.6) 3 (8.8) 20 (17.7) 10 (8.8)
Dry skin 7 (17.5) 0 10 (29.4) 0 20 (17.7) 0
Hyperglycemia 4 (10.0) 2 (5.0) 3 (8.8) 0 19 (16.8) 3 (2.7)
Decreased appetite 8 (20.0) 0 5 (14.7) 0 18 (15.9) 2 (1.8)
Asthenia 4 (10.0) 1 (2.5) 6 (17.6) 1 (2.9) 17 (15.0) 3 (2.7)
Hypertension 4 (10.0) 1 (2.5) 6 (17.6) 1 (2.9) 12 (10.6) 2 (1.8)
Pruritus 0 0 9 (26.5) 2 (5.9) 11 (9.7) 3 (2.7)
Thrombocytopenia 3 (7.5) 1 (2.5) 6 (17.6) 4 (11.8) 11 (9.7) 6 (5.3)
Skin ﬁssures 6 (15.0) 0 4 (11.8) 0 10 (8.8) 0
Dysphagia 2 (5.0) 0 5 (14.7) 1 (2.9) 8 (7.1) 1 (0.9)
Face edema 3 (7.5) 0 4 (11.8) 0 8 (7.1) 0
Edema peripheral 4 (10.0) 0 2 (5.9) 0 8 (7.1) 0
Dysgeusia 3 (7.5) 0 3 (8.8) 0 7 (6.2) 0
Lipase increased 5 (12.5) 3 (7.5) 1 (2.9) 1 (2.9) 7 (6.2) 4 (3.5)
Abdominal pain 2 (5.0) 0 1 (2.9) 0 6 (5.3) 0
Rash 1 (2.5) 0 1 (2.9) 0 6 (5.3) 0
Xerosis 1 (2.5) 0 1 (2.9) 1 (2.9) 6 (5.3) 2 (1.8)
Abbreviation: CK, creatine phosphokinase.
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Antitumor activity and pharmacodynamics
Of 113 evaluable patients in the study, 7 [6.2%; 90% conﬁ-
dence interval (CI), 2.9–11.3; 6 ovarian and 1 NSCLC patients
harboring KRAS mutations] had a best response of partial or
complete responses (PR or CR).
Of the 21 patients with ovarian cancer, 4 were enrolled in the
dose-escalation phase and 17 in the dose-expansion phase (Table
1A). The majority were well-differentiated serous cancer (15
patients, 71%) and were KRAS mutated (19 patients,
91%); Table 1B summarizes additional characteristics. These
patients were heavily pretreated with median of three prior lines
of therapy (range, 1–14). ORR was 29% (1 conﬁrmed CR, 5
conﬁrmed PR) and 50% at RP2D (1 conﬁrmed CR and 3 con-
ﬁrmed PR; Table 3). An additional 2 (10%) of 21 patients
experienced a best target lesion reduction of at least 30%without
subsequent conﬁrmation of response (one progressed, and the
second underwent resection of nontarget lesion; Fig. 3A). DCR
was 76% andmedian duration of SDwas 11months. Median PFS
in all patients with ovarian cancer was 7 months (95% CI, 4.2–
12.9). At time of analysis data cutoff date, median OS was not
reached as a majority (18 patients, 86%) of patients with ovarian
were alive. Three patients were continuing on study treatment as
of July 18, 2013; one patient with ovarian cancer and CR subse-
quently progressed in December 2013 at cycle 15, 1 patient with
NSCLC with SD progressed in August 2013 after 8 cycles and the
thirdpatientwithovarian cancer and SDwas still ongoingon cycle
19 as of June 2014.
Of the 17 patients withNSCLC, 9 (53%) achieved a best overall
response (BOR) of SD and 1 (6%) patient with KRAS mutation
attained conﬁrmed PR (Fig. 3A). One additional patient with
NSCLC (6%) experienced a best percentage reduction of 54% in
sumof longest diameters (SLD)without subsequent conﬁrmation
of the response criterion (Fig. 3A). Median PFS was 4 months
(95% CI, 1.8–5.3) and median OS was 5 months (95% CI, 3.9–
NA). For the patients with pancreatic cancer, 12 (50%) achieved a
BOR of SD. Median PFS was 2 months (95% CI, 1.8–3.4) and
median OS was almost 5 months (95% CI, 3.8–5.8).
Multiple linear regression models were performed to estimate
the association with the best percentage change in SLD. There was
no statistically signiﬁcant exposure–response relationship, poten-
tially due to the limited number of patients treated. Treatment
duration exposure data of patients who started at MTD or RP2D
dose illustrated that most responders had a durable response
despite reductions from the starting dose (Supplementary Figs. S2
and S3).
For the PD assessment, a reduction in expression of p-S6 and p-
ERK was observed relative to baseline. Overall, mean percentage
change in the cytoplasmic levels of p-S6-240, p-S6-235, and
p-ERK from baseline at cycle 1 day 28 was 25% (n ¼ 8),
14%(n¼8), and34%(n¼4), respectively.Highest inhibition
of pS6-235was observed in 2 patients with ovarian cancer (56.2%
and48.1%decrease frombaseline, respectively), bothwere partial
responders. There was no evidence of strong corresponding p-S6-
240 or p-ERK inhibition and one of these 2 partial responders
showed even increase of p-ERK levels when on study treatment.
Overall, it was not possible to determine any association between
efﬁcacy and PD markers, possibly due to limited available data
(Supplementary Fig. S1A–S1C).
Exploratory analyses examined any relationship between
molecular status at baseline and efﬁcacy (Fig. 3A andB). Although
not statistically signiﬁcant, patients with ovarian cancer with a
KRAS G12V alteration appeared to be more responsive to study
treatment comparedwith patientswith other alterations (Fig. 3B).
These analyses were hypothesis generating, and outcome should
be interpreted cautiously because of small sample size with
further study needed to conﬁrm. No clear associations between
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dosing of buparlisib and trametinib—
cycle 1 day 15.
Table 3. Patients ovarian cancer: BOR
Buparlisib 60 mg þ
trametinib 1 mg (N ¼ 1)
Buparlisib 60 mg þ
trametinib 1.5 mg (N ¼ 8)
Buparlisib 70 mg þ
trametinib 1.5 mg (N ¼ 12)
All patients
(N ¼ 21)
BOR n (%) n (%) n (%) n (%)
CR 0 1 (12.5) 0 1 (4.8)
PR 0 3 (37.5) 2 (16.7) 5 (23.8)
SD 0 2 (25.0) 8 (66.7) 10 (47.6)
Progressive disease 0 1 (12.5) 1 (8.3) 2 (9.5)
Unknown 1 (100.0) 1 (12.5) 1 (8.3) 3 (14.3)
ORR (CR or PR) 0 4 (50.0) 2 (16.7) 6 (28.6)
DCR (CR or PR or SD) 0 6 (75.0) 10 (83.3) 16 (76.2)
Abbreviation: SD, stable disease, deﬁned as at least one SD assessment (or better) >6 weeks after start of treatment (and not qualifying for CR or PR).
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markers relevant to PI3K andMAPK pathways and clinical activity
were found (Fig. 3A).
Discussion
This phase 1b study demonstrated that oral pan-PI3K inhibitor
buparlisib and oral MEK1/2 inhibitor trametinib can be safely
combined with an RP2D of buparlisib 60 mg and trametinib 1.5
mg daily in patients with BRAF/RAS-mutant solid tumors. The
relative dose intensity reﬂected better tolerability with RP2D
compared with MTD of the combination. However, long-term
treatment was very challenging for both dose combinations.
Other PI3K and MEK inhibitor combination studies have shown
similar toxicity proﬁles to this study,with fatigue, gastrointestinal,
and cutaneous toxicity being most predominant (17–22), limit-
ing ability to administer both agents at the single-agent MTDs in
combination.
Exposure and maximum concentration of buparlisib
appeared to be lower than in the ﬁrst-in-man (FIM) study
(CBKM120X2101; ref. 10) both after a single dose and at steady
state, although the accumulation ratios of AUC0-24 on days 15
and 28 were similar to what was observed in monotherapy,
suggesting that this decrease might be due to a change in
bioavailability. Similar phenomenon was observed in other
combination trials; however, the underlying mechanism is
unknown.
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Exposure of trametinib appeared to be increased in the com-
bination compared with the 2 mg dose in the FIM study (13),
whereas no major change in its maximum concentration was
observed. Accumulation of trametinib is highly variablemaking it
difﬁcult to establish if this increased exposure is due to a potential
interaction with buparlisib. When comparing known PK charac-
teristics of the two drugs, no clear mechanism could be identiﬁed
for a potential interaction.
Preliminary results in other PI3K and MEK inhibitor combi-
nation studies have shown early signs of antitumor activity in
colorectal cancer, renal cell carcinoma, ovarian cancer, NSCLC,
endometrial cancer, melanoma, and prostate cancer (17, 19–21).
In a recent phase I trial testing SAR245409 (PI3K/mTOR inhib-
itor) combinedwith pimasertib in 46 patients, there were two PRs
with the combination (KRAS-mutated colorectal cancer with
neuroendocrine features and KRAS/PIK3CA–mutated low-grade
ovarian cancer; ref. 19).
In our study, promising antitumor activity [ORR 29% (at RP2D
ORR was 50%), DCR 76%, and median PFS 7 months] was
observed in RAS/BRAF–mutant ovarian cancer. In a phase II study
of single-agent MEK inhibitor selumetinib in 52 patients with
low-grade serous ovarian carcinoma, CR or PR was observed in 8
patients (15%), SD was observed in 34 patients (65%), and
median PFS was 11.0 months (23). There were 14 of 34 (41%)
patients with KRASmutations, of which 2 (14%) showed a tumor
response; this was not signiﬁcantly different from the 25%
response rate in KRAS wild-type tumors (5/20 patients; P ¼
0.672); however, median PFS in patients with ovarian cancer
with KRAS mutations was not reported (23). Two ongoing trials
are investigating MEK inhibitors in low-grade serous ovarian
cancer: A phase III study with single-agent MEK inhibitor bini-
metinib (MEK162, MILO study) and a phase II/III study with
trametinib.
Alternative dosing schedules of this combination might
improve long-term tolerability. Currently, a phase 1b, open-label
study (CMEK162X2109) is evaluating an alternative schedule of
the PI3Ka inhibitor BYL719 combined with MEK inhibitor bini-
metinib MEK162 (MEK162 given 14 days on, followed by 7 days
off and continuous dosing of BYL719) in patients with RAS- or
BRAF-mutant advanced solid malignancies, such as ovarian
cancer.
It has been shown that targeting the PI3K/AKT/mTOR pathway
seldom works when a single agent is used (24). The current
generation of PI3K inhibitors is designed to producemore speciﬁc
inhibition and potentially improve toxicity proﬁles, although
none are currently approved for treatment of ovarian cancer.
Activation of these pathways and role played in promoting
ovarian cancers are not completely understood (25). Results of
our study indicate that buparlisib and trametinib combination
treatment can inhibit PI3K and MAPK pathway signaling,
although it is unclear if the degree of suppression achieved with
plasma concentrations delivered is sufﬁcient for sustained path-
way blockade.
Our ﬁndings demonstrate clinical activity of a PI3K and MEK
inhibitor combination in KRAS-mutant ovarian cancer, for
which there is a lack of effective treatment options. We
observed a higher ORR in patients with KRAS-mutant ovarian
cancer compared with a single-agent MEK inhibitor in the same
population. A hypothesis might be that PI3K and MEK inhib-
itor combination therapy is more active in certain KRAS-mutant
genotypes such as G12V. Although not statistically signiﬁcant,
patients in this study with KRAS G12V–mutated ovarian can-
cers seemed to beneﬁt more from the combination treatment.
Emerging evidence in colorectal cancer and NSCLC (26–28)
indicates that not all KRAS-mutant genotypes are alike in terms
of their biology, and may respond differently to the same
treatment. However, additional data are required to evaluate
this hypothesis. Various questions arise from our data, includ-
ing whether KRAS mutation is a predictive biomarker in low-
grade serous ovarian cancer, and whether other histologic
subtypes of ovarian cancers with RAS mutations will beneﬁt
from MEK inhibitor therapy or PI3K and MEK inhibitor com-
binations. To further investigate sensitivity of low-grade ovar-
ian cancer and the role of KRAS mutations and signaling
pathways in PI3K and MEK inhibitor combination therapy,
additional studies are warranted.
The combination of oral pan-PI3K inhibitor buparlisib and
MEK1/2 inhibitor trametinib has anMTDofbuparlisib 70mgand
trametinib 1.5 mg daily and an RP2D of buparlisib 60 mg and
trametinib 1.5 mg daily in patients with mutant BRAF/RAS solid
tumors. Predominant toxicities of the combination were gastro-
intestinal and dermatologic, requiring frequent dose interruption
and/or dose modiﬁcation. This oral combination demonstrated
promising antitumor efﬁcacy for patientswithovarian cancerwith
KRAS-mutant tumors.
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